ClinicalTrials.gg
RecruitingNCT04800458APATUpdated Jun 1, 2026

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

An interventional study of Blood samples in Thrombocytopenia, Immune Thrombocytopenia and Myelodysplasia, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Primary conditionPurpura, Thrombocytopenic, IdiopathicRegistry: ThrombocytopeniaReclassifiedWhy we changed it
Registry
Thrombocytopenia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Purpura, Thrombocytopenic, Idiopathic
Why
  1. The study's listed conditions name Purpura, Thrombocytopenic, Idiopathic, a narrower term within Thrombocytopenia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
225
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux — 5 open to participants now, 5 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · University Hospital, Bordeaux.

Started
2021
the only one that year
No phase
4 of 12
3 open now
Registered
8th of 12
by date

Among the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux, this one is the only one that started in 2021, is one of 4 with no phase, and was the 8th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Purpura, Thrombocytopenic, Idiopathic by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.

03

Conditions studied

  • Thrombocytopenia
  • Immune Thrombocytopenia
  • Myelodysplasia

Browse trials for

Keywords

  • Monoclonal antibody immobilization of platelet antigens assay
  • MAIPA
  • Anti-platelet antibodies
  • Thrombopoietin
04

In context

Purpura, Thrombocytopenic, Idiopathic Reclassified

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

This study's planned enrollment of 225 is above the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.

Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thrombocytopenia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years old;
  • Patients with thrombocytopenia \<100 G/L, checked twice, having ruled out false thrombocytopenia by aggregation and acute leukemia by smear;
  • No treatment started;
  • Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);
  • Person affiliated or benefiting from a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Secondary ITP;
  • False thrombocytopenia;
  • Patients who have been transfused with for less than 7 days with efficacy;
  • Patient treated for thrombocytopenia (48 hours of therapy is tolerated and is not an exclusion criteria);
  • Patient with acute leukemia;
  • Pregnant or breastfeeding woman;
  • False thrombocytopenia;
  • Patient under guardianship, curatorship or any other legal protection regime.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    thrombocytopenic patients

    Biological: Blood samples

Interventions

  • BiologicalBlood samples

    * Thrombopoietin : 7 ml whole blood. * Anti-platelet antibodies free : 14 ml whole blood. * Anti-platelet antibodies bound : If the platelet count is ≥ 50 G / L : 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 50 G / L and ≥ 20 G / L : 28 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 20 G / L and ≥ 10 G / L: 42 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation ; If the platelet count is \< 10 G / L : 49 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation.

07

What researchers measure

Primary outcomes

  1. Percentage of patients with a diagnosis of autoimmune thrombocytopenia among those in whom will be identified anti-platelet antibodies in direct and indirect MAIPA

    Time frame: 12 months after baseline

Secondary outcomes

  1. Percentage of patients with chronic ITP

    Time frame: 12 months after baseline

  2. serum Thrombopoietin concentration

    Time frame: At baseline and 12 months after baseline

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for May 2028, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 16, 2021
StartActual
May 19, 2021
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04800458
Collaborators
Ministry for Health and Solidarity, France
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
May 19, 2021
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

Jean-François VIALLARD, Prof
Contact
jean-françois.viallard@chu-bordeaux.fr
05.57.65.64.83 ext. +33
Jean-François VIALLARD, Prof
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion